388 related articles for article (PubMed ID: 16731060)
1. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis.
Testoni PA; Mariani A; Masci E; Curioni S
Dig Liver Dis; 2006 Aug; 38(8):588-95. PubMed ID: 16731060
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological prevention of post-ERCP pancreatitis--an everlasting dream?
Hellmig S; Fölsch UR
Dig Liver Dis; 2006 Aug; 38(8):596-8. PubMed ID: 16731061
[No Abstract] [Full Text] [Related]
3. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
Manes G; Ardizzone S; Lombardi G; Uomo G; Pieramico O; Porro GB
Gastrointest Endosc; 2007 Jun; 65(7):982-7. PubMed ID: 17531632
[TBL] [Abstract][Full Text] [Related]
4. Preventing post-ERCP pancreatitis: where are we?
Testoni PA
JOP; 2003 Jan; 4(1):22-32. PubMed ID: 12555013
[TBL] [Abstract][Full Text] [Related]
5. Gabexate in the prophylaxis of post-ERCP pancreatitis: a meta-analysis of randomized controlled trials.
Zheng M; Chen Y; Yang X; Li J; Zhang Y; Zeng Q
BMC Gastroenterol; 2007 Feb; 7():6. PubMed ID: 17295917
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic administration of somatostatin or gabexate does not prevent pancreatitis after ERCP: an updated meta-analysis.
Andriulli A; Leandro G; Federici T; Ippolito A; Forlano R; Iacobellis A; Annese V
Gastrointest Endosc; 2007 Apr; 65(4):624-32. PubMed ID: 17383459
[TBL] [Abstract][Full Text] [Related]
7. Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors.
Christoforidis E; Goulimaris I; Kanellos I; Tsalis K; Demetriades C; Betsis D
Endoscopy; 2002 Apr; 34(4):286-92. PubMed ID: 11932783
[TBL] [Abstract][Full Text] [Related]
8. Risk for post-ERCP pancreatitis after needle knife precut sphincterotomy following repeated cannulation attempts.
Lee JK; Park JK; Yoon WJ; Lee SH; Lee KH; Ryu JK; Kim YT; Yoon YB
J Clin Gastroenterol; 2007 Apr; 41(4):427-31. PubMed ID: 17413615
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin and gabexate for post-endoscopic retrograde cholangiopancreatography pancreatitis prevention: meta-analysis of randomized placebo-controlled trials.
Rudin D; Kiss A; Wetz RV; Sottile VM
J Gastroenterol Hepatol; 2007 Jul; 22(7):977-83. PubMed ID: 17559376
[TBL] [Abstract][Full Text] [Related]
10. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
Cavallini G; Tittobello A; Frulloni L; Masci E; Mariana A; Di Francesco V
N Engl J Med; 1996 Sep; 335(13):919-23. PubMed ID: 8786777
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis.
Masci E; Cavallini G; Mariani A; Frulloni L; Testoni PA; Curioni S; Tittobello A; Uomo G; Costamagna G; Zambelli S; Macarri G; Innocenti P; Dragonetti C;
Am J Gastroenterol; 2003 Oct; 98(10):2182-6. PubMed ID: 14572565
[TBL] [Abstract][Full Text] [Related]
12. Protease inhibitors for prevention of ERCP pancreatitis: can we afford the price of success?
Ziebert JJ; Bjorkman DJ
Am J Gastroenterol; 1997 Jun; 92(6):1067-8. PubMed ID: 9177543
[No Abstract] [Full Text] [Related]
13. Pancreatic-stent placement for prevention of post-ERCP pancreatitis: a cost-effectiveness analysis.
Das A; Singh P; Sivak MV; Chak A
Gastrointest Endosc; 2007 Jun; 65(7):960-8. PubMed ID: 17331513
[TBL] [Abstract][Full Text] [Related]
14. Antisecretory vs. antiproteasic drugs in the prevention of post-ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study.
Andriulli A; Caruso N; Quitadamo M; Forlano R; Leandro G; Spirito F; De Maio G
JOP; 2003 Jan; 4(1):41-8. PubMed ID: 12555015
[TBL] [Abstract][Full Text] [Related]
15. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial.
Lee KT; Lee DH; Yoo BM
Pancreas; 2008 Nov; 37(4):445-8. PubMed ID: 18953260
[TBL] [Abstract][Full Text] [Related]
16. Rectal indomethacin or intravenous gabexate mesylate as prophylaxis for acute pancreatitis post-endoscopic retrograde cholangiopancreatography.
Guglielmi V; Tutino M; Guerra V; Giorgio P
Eur Rev Med Pharmacol Sci; 2017 Nov; 21(22):5268-5274. PubMed ID: 29228444
[TBL] [Abstract][Full Text] [Related]
17. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial.
Li ZS; Pan X; Zhang WJ; Gong B; Zhi FC; Guo XG; Li PM; Fan ZN; Sun WS; Shen YZ; Ma SR; Xie WF; Chen MH; Li YQ
Am J Gastroenterol; 2007 Jan; 102(1):46-51. PubMed ID: 17266687
[TBL] [Abstract][Full Text] [Related]
18. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
Andriulli A; Clemente R; Solmi L; Terruzzi V; Suriani R; Sigillito A; Leandro G; Leo P; De Maio G; Perri F
Gastrointest Endosc; 2002 Oct; 56(4):488-95. PubMed ID: 12297762
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis of post-ERCP pancreatic complications with gabexate.
Piscaglia F; Righini R; Tewelde AG
Dig Liver Dis; 2007 Mar; 39(3):291; author reply 291. PubMed ID: 17267312
[No Abstract] [Full Text] [Related]
20. Prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis by an endoscopic pancreatic spontaneous dislodgement stent.
Sofuni A; Maguchi H; Itoi T; Katanuma A; Hisai H; Niido T; Toyota M; Fujii T; Harada Y; Takada T
Clin Gastroenterol Hepatol; 2007 Nov; 5(11):1339-46. PubMed ID: 17981247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
